JP6153862B2 - 異種間特異的なＰＳＭＡｘＣＤ３二重特異性単鎖抗体 - Google Patents

異種間特異的なＰＳＭＡｘＣＤ３二重特異性単鎖抗体 Download PDF

Info

Publication number
JP6153862B2
JP6153862B2 JP2013501861A JP2013501861A JP6153862B2 JP 6153862 B2 JP6153862 B2 JP 6153862B2 JP 2013501861 A JP2013501861 A JP 2013501861A JP 2013501861 A JP2013501861 A JP 2013501861A JP 6153862 B2 JP6153862 B2 JP 6153862B2
Authority
JP
Japan
Prior art keywords
seq
cdr
single chain
nos
bispecific single
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013501861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528569A5 (enExample
JP2013528569A (ja
Inventor
ピーター クーファー、
ピーター クーファー、
トビアス ラウム、
トビアス ラウム、
ロマン キッシェル、
ロマン キッシェル、
ラルフ ルーターヴェセ、
ラルフ ルーターヴェセ、
パトリック ホフマン、
パトリック ホフマン、
ドリス ラウ、
ドリス ラウ、
スザンヌ マンゴルド、
スザンヌ マンゴルド、
マッティアス クリンゲル、
マッティアス クリンゲル、
エブリンヌ シェラ、
エブリンヌ シェラ、
スザンヌ ハウスマン、
スザンヌ ハウスマン、
ペトラ フルール、
ペトラ フルール、
カローラ ステガー、
カローラ ステガー、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH filed Critical Amgen Research Munich GmbH
Publication of JP2013528569A publication Critical patent/JP2013528569A/ja
Publication of JP2013528569A5 publication Critical patent/JP2013528569A5/ja
Application granted granted Critical
Publication of JP6153862B2 publication Critical patent/JP6153862B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013501861A 2010-04-01 2011-04-01 異種間特異的なＰＳＭＡｘＣＤ３二重特異性単鎖抗体 Active JP6153862B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32005210P 2010-04-01 2010-04-01
US61/320,052 2010-04-01
PCT/EP2011/055104 WO2011121110A1 (en) 2010-04-01 2011-04-01 CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY

Publications (3)

Publication Number Publication Date
JP2013528569A JP2013528569A (ja) 2013-07-11
JP2013528569A5 JP2013528569A5 (enExample) 2014-05-08
JP6153862B2 true JP6153862B2 (ja) 2017-06-28

Family

ID=44198856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013501861A Active JP6153862B2 (ja) 2010-04-01 2011-04-01 異種間特異的なＰＳＭＡｘＣＤ３二重特異性単鎖抗体

Country Status (17)

Country Link
US (1) US9587036B2 (enExample)
EP (1) EP2552964B1 (enExample)
JP (1) JP6153862B2 (enExample)
KR (1) KR101799922B1 (enExample)
CN (2) CN107090044A (enExample)
AR (1) AR080868A1 (enExample)
AU (1) AU2011234443B2 (enExample)
BR (1) BR112012024964B1 (enExample)
CA (1) CA2793139C (enExample)
IL (1) IL222197A0 (enExample)
MX (1) MX348360B (enExample)
NZ (1) NZ602209A (enExample)
RU (1) RU2617942C2 (enExample)
SG (1) SG183937A1 (enExample)
TW (1) TWI653333B (enExample)
WO (1) WO2011121110A1 (enExample)
ZA (1) ZA201206572B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2356153T3 (en) * 2008-10-01 2016-07-04 Amgen Res Munich Gmbh Bispecific single CHAIN ​​PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
CA2738566C (en) * 2008-10-01 2024-04-30 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
BRPI0919840B1 (pt) * 2008-10-01 2023-02-28 Amgen Research (Munich) Gmbh Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
PL2647707T3 (pl) 2010-11-30 2019-02-28 Chugai Seiyaku Kabushiki Kaisha Środek terapeutyczny wywołujący cytotoksyczność
AU2012245260B2 (en) 2011-04-22 2016-09-08 Aptevo Research And Development Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
SMT201900239T1 (it) * 2011-05-21 2019-05-10 Macrogenics Inc Molecole di legame a cd3 in grado di legare cd3 umano e non umano
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
EP3620473A1 (en) 2013-01-14 2020-03-11 Xencor, Inc. Novel heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
GB201303308D0 (en) * 2013-02-25 2013-04-10 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
ES2776706T3 (es) 2013-07-05 2020-07-31 Genmab As Anticuerpos contra CD3 humanizados o quiméricos
RU2727836C2 (ru) 2013-07-25 2020-07-24 Сайтомкс Терапьютикс, Инк. Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения
EP3736292B1 (en) 2013-12-17 2024-05-08 Genentech, Inc. Anti-cd3 antibodies and methods of use
KR20230022270A (ko) 2014-03-28 2023-02-14 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
EP3164417A1 (en) 2014-07-01 2017-05-10 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
EP3172235A2 (en) 2014-07-25 2017-05-31 Cytomx Therapeutics Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016016859A1 (en) * 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
EP2982693A1 (en) 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
WO2016023019A2 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CU24597B1 (es) 2014-11-26 2022-05-11 Xencor Inc Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
CN107709363A (zh) * 2015-05-01 2018-02-16 基因泰克公司 掩蔽抗cd3抗体和使用方法
EP3291836A4 (en) * 2015-05-06 2018-11-14 Janssen Biotech, Inc. Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
WO2016182064A1 (ja) * 2015-05-13 2016-11-17 中外製薬株式会社 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
CN114652827A (zh) 2015-05-29 2022-06-24 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白质的使用方法
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
US10227410B2 (en) * 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US10781264B2 (en) * 2016-02-03 2020-09-22 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs
KR102466763B1 (ko) * 2016-04-13 2022-11-11 오리맵스 리미티드 항- psma 항체 및 이의 용도
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
MX2018016404A (es) 2016-06-21 2019-10-15 Teneobio Inc Anticuerpos de union a cd3.
EP4050032A1 (en) 2016-06-28 2022-08-31 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
IL313895A (en) * 2016-09-14 2024-08-01 Teneoone Inc CD3 binding antibodies
US10689461B2 (en) 2016-09-15 2020-06-23 Novimmune Sa Antibody dual display dual compositions and methods of use thereof
NZ792355A (en) * 2016-10-11 2025-12-19 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
MX2019007379A (es) 2016-12-21 2019-09-18 Teneobio Inc Anticuerpos anti-bcma unicamente de cadena pesada.
CA3053010A1 (en) 2017-02-08 2018-08-16 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
JP7685821B2 (ja) 2017-02-20 2025-05-30 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質
JP7029822B2 (ja) * 2017-03-29 2022-03-04 タイペイ・メディカル・ユニバーシティ 抗原特異的ｔ細胞及びその使用
CN117567624A (zh) 2017-06-20 2024-02-20 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
CN117866097A (zh) 2017-06-20 2024-04-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
RS64419B1 (sr) 2017-08-03 2023-09-29 Alector Llc Anti-trem2 antitela i postupci za njihovu upotrebu
AU2018347607B2 (en) 2017-10-14 2025-08-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN112272563A (zh) 2017-11-08 2021-01-26 Xencor股份有限公司 使用新颖抗pd-1序列的双特异性和单特异性抗体
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
BR112020012554A2 (pt) 2017-12-22 2020-11-24 Teneobio, Inc. anticorpos de cadeia pesada que se ligam a cd22
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
CA3090236A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007390YA (en) 2018-02-08 2020-08-28 Genentech Inc Bispecific antigen-binding molecules and methods of use
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
CN120399075A (zh) 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
SI3830132T1 (sl) * 2018-07-31 2023-03-31 Heidelberg Pharma Research Gmbh Humanizirana protitelesa proti PSMA
MA53284A (fr) 2018-08-08 2022-01-26 Dragonfly Therapeutics Inc Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020072821A2 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
EP3930850A1 (en) 2019-03-01 2022-01-05 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
CR20210500A (es) 2019-04-05 2021-11-05 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
CN112390884B (zh) * 2019-04-09 2022-07-08 苏州大学 Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用
EA202290054A1 (ru) 2019-06-14 2022-03-25 Тенеобио, Инк. Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
WO2021004400A1 (zh) * 2019-07-06 2021-01-14 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
CN120842421A (zh) * 2019-07-30 2025-10-28 魁尔斯弗生物治疗股份有限公司 双特异性抗LRRC15和CD3ε抗体
EP4072584B1 (en) 2019-12-13 2026-01-28 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
US20230151102A1 (en) 2020-01-13 2023-05-18 Aptevo Research And Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
MX2022008654A (es) 2020-01-13 2022-08-18 Aptevo Res & Development Llc Formulaciones para productos terapeuticos proteicos.
IL297922A (en) 2020-05-06 2023-01-01 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and clec12a
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
MX2023005132A (es) 2020-11-04 2023-05-25 Genentech Inc Dosificacion para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3.
US12516118B2 (en) 2020-11-04 2026-01-06 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies and anti-CD79b antibody drug conjugates
CA3196076A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
EP4240768A2 (en) 2020-11-06 2023-09-13 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
WO2022125583A1 (en) * 2020-12-09 2022-06-16 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
MX2023006817A (es) * 2020-12-09 2023-08-14 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
KR20240005691A (ko) 2021-04-30 2024-01-12 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
EP4334358A1 (en) 2021-05-06 2024-03-13 Amgen Research (Munich) GmbH Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
AU2022273541A1 (en) 2021-05-14 2023-11-30 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
EP4341291A1 (en) 2021-05-21 2024-03-27 Aptevo Research and Development LLC Dosing regimens for protein therapeutics
CA3253777A1 (en) 2022-03-21 2023-09-28 Amgen Inc. Polytherapeutic methods with T-lymphocyte-activating molecules for treating prostate cancer
CA3256681A1 (en) 2022-05-12 2023-11-16 Amgen Research (Munich) Gmbh MULTI-TARGET, BI-SPECIFIC MOLECULES WITH MULTIPLE ANTIGEN-BINDING CHAINS AND INCREASED SELECTIVITY

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
GB9304200D0 (en) 1993-03-02 1993-04-21 Sandoz Ltd Improvements in or relating to organic compounds
WO1994029469A2 (en) 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
WO1997000957A1 (en) 1995-06-23 1997-01-09 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
CA2309679C (en) 1997-11-17 2010-07-20 Peter Kufer Method of identifying binding site domains that retain the capacity of binding to an epitope
WO1999054440A1 (en) 1998-04-21 1999-10-28 Micromet Gesellschaft Für Biomedizinische Forschung Mbh CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
RU2179862C1 (ru) * 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
WO2004106380A2 (en) 2003-05-31 2004-12-09 Micromet Ag Human-anti-human cd3 binding molecules
SI1673398T1 (sl) * 2003-10-16 2011-05-31 Micromet Ag Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
JP2008529556A (ja) 2005-02-18 2008-08-07 メダレックス， インク． 前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
EA014025B1 (ru) 2005-09-12 2010-08-30 Новиммун С.А. Композиции антитела против cd3
EP3178850B1 (en) * 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
WO2007059190A2 (en) * 2005-11-14 2007-05-24 Psma Development Company, Llc. Compositions of and methods of using stabilized psma dimers
WO2008119566A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
EP3461842A1 (en) 2007-04-03 2019-04-03 Amgen Research (Munich) GmbH Cross-species-specific binding domain
KR101589759B1 (ko) * 2007-04-03 2016-01-29 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 ｃｄ３―입실론 결합 도메인
CA2695382A1 (en) * 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health Of Human Services, National Institutes Of A fold-back diabody diphtheria toxin immunotoxin and methods of use
JP4970211B2 (ja) * 2007-10-18 2012-07-04 ヘキサゴン・メトロジー株式会社 ３次元形状測定器
CA2738566C (en) * 2008-10-01 2024-04-30 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
DK2356153T3 (en) * 2008-10-01 2016-07-04 Amgen Res Munich Gmbh Bispecific single CHAIN ​​PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES
CA2738568C (en) * 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
BRPI0919840B1 (pt) 2008-10-01 2023-02-28 Amgen Research (Munich) Gmbh Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function

Also Published As

Publication number Publication date
ZA201206572B (en) 2019-10-30
AU2011234443B2 (en) 2014-05-22
KR101799922B1 (ko) 2017-11-21
CA2793139A1 (en) 2011-10-06
NZ602209A (en) 2014-08-29
EP2552964A1 (en) 2013-02-06
TW201134942A (en) 2011-10-16
IL222197A0 (en) 2012-12-31
RU2617942C2 (ru) 2017-04-28
SG183937A1 (en) 2012-10-30
EP2552964B1 (en) 2019-10-02
KR20130088013A (ko) 2013-08-07
CN107090044A (zh) 2017-08-25
BR112012024964B1 (pt) 2021-05-25
US9587036B2 (en) 2017-03-07
MX2012011405A (es) 2013-01-29
BR112012024964A2 (pt) 2017-07-18
AR080868A1 (es) 2012-05-16
WO2011121110A1 (en) 2011-10-06
AU2011234443A1 (en) 2012-09-27
JP2013528569A (ja) 2013-07-11
CA2793139C (en) 2023-08-08
TWI653333B (zh) 2019-03-11
US20130129730A1 (en) 2013-05-23
RU2012143519A (ru) 2014-05-10
MX348360B (es) 2017-06-07
CN103025759A (zh) 2013-04-03

Similar Documents

Publication Publication Date Title
JP6153862B2 (ja) 異種間特異的なＰＳＭＡｘＣＤ３二重特異性単鎖抗体
JP7273106B2 (ja) 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
US11987633B2 (en) Cross-species-specific single domain bispecific single chain antibody
HK1176366A (en) Cross-species-specific psmaxcd3 bispecific single chain antibody
HK1176366B (en) Cross-species-specific psmaxcd3 bispecific single chain antibody
HK1232556A (en) Cross-species-specific psmaxcd3 bispecific single chain antibody
HK1232556A1 (en) Cross-species-specific psmaxcd3 bispecific single chain antibody
HK1158669B (en) Cross-species-specific psmaxcd3 bispecific single chain antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160712

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170131

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170207

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20170301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170531

R150 Certificate of patent or registration of utility model

Ref document number: 6153862

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250